Clinical Validations for IV-Cell™ and HemeScreen™ Completed
26 sept. 2019 10h53 HE
|
Precipio, Inc.
Orders expected from several major labs both domestically and internationally NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),...
Precipio and University of Pennsylvania Enter into Joint Collaboration Agreement for Pathology Diagnostics
05 sept. 2019 09h15 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Specialty Diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today a major development toward expanding cancer patient access to world...
Precipio Regains Nasdaq Listing Compliance
15 mai 2019 11h40 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 15, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on May 15, 2019 the Company received a letter from Nasdaq informing...
Delays in Celiac Disease Diagnoses Remain Painful and Costly for Canadians
01 mai 2019 09h14 HE
|
Canadian Celiac Association
TORONTO, May 01, 2019 (GLOBE NEWSWIRE) -- Did you know that on average Canadians with undetected celiac disease go 10 – 12 years before receiving a positive diagnosis, according to recent studies?1 ...
Innovation Behind Precipio’s ICE-COLD PCR™ Platform Spotlighted in Media
18 oct. 2018 07h36 HE
|
Precipio, Inc.
Articles Highlight Scientific and Economic Advantages Provided by Precipio’s Technology NEW HAVEN, Conn., Oct. 18, 2018 (GLOBE NEWSWIRE) -- The scientific and economic advantages of the...
Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues
16 oct. 2018 07h47 HE
|
Precipio, Inc.
Fourth consecutive Quarter of Triple-Digit Year-over-Year Quarterly Revenue Growth; Year-to-Date Revenues Increased 163% over First Three Quarters of 2017 NEW HAVEN, Conn., Oct. 16, 2018 (GLOBE...
Precipio Granted 180 Day NASDAQ Extension to Regain Compliance
27 sept. 2018 07h37 HE
|
Precipio, Inc.
Enables Company to execute on strategic and commercial initiatives with the goal of meeting the minimum $1.00 price target NEW HAVEN, Conn., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Specialty cancer...
Precipio and Nucleai Partner to Develop Artificial Intelligence-Powered Hemepath Solution
26 juin 2018 08h00 HE
|
Precipio, Inc.
System will support Hematopathologists in accurately identifying abnormalities to ensure diagnostic accuracy NEW HAVEN, Conn., June 26, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company...